skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: New developments on AIDS-related cancers: The role of the delay and treatment options

Authors:
ORCiD logo [1]; ORCiD logo [2]
  1. Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n 4440-452 Porto Portugal
  2. School of Engineering, Polytechnic of Porto, Rua Dr António Bernardino de Almeida 431, 4249-015 Porto Portugal
Publication Date:
Sponsoring Org.:
USDOE Office of Nuclear Energy (NE), Fuel Cycle Technologies (NE-5)
OSTI Identifier:
1408250
Grant/Contract Number:
SFRH/BD/96816/2013
Resource Type:
Journal Article: Publisher's Accepted Manuscript
Journal Name:
Mathematical Methods in the Applied Sciences
Additional Journal Information:
Related Information: CHORUS Timestamp: 2017-11-10 04:22:03; Journal ID: ISSN 0170-4214
Publisher:
Wiley Blackwell (John Wiley & Sons)
Country of Publication:
Germany
Language:
English

Citation Formats

Carvalho, Ana R. M., and Pinto, Carla M. A. New developments on AIDS-related cancers: The role of the delay and treatment options. Germany: N. p., 2017. Web. doi:10.1002/mma.4657.
Carvalho, Ana R. M., & Pinto, Carla M. A. New developments on AIDS-related cancers: The role of the delay and treatment options. Germany. doi:10.1002/mma.4657.
Carvalho, Ana R. M., and Pinto, Carla M. A. 2017. "New developments on AIDS-related cancers: The role of the delay and treatment options". Germany. doi:10.1002/mma.4657.
@article{osti_1408250,
title = {New developments on AIDS-related cancers: The role of the delay and treatment options},
author = {Carvalho, Ana R. M. and Pinto, Carla M. A.},
abstractNote = {},
doi = {10.1002/mma.4657},
journal = {Mathematical Methods in the Applied Sciences},
number = ,
volume = ,
place = {Germany},
year = 2017,
month =
}

Journal Article:
Free Publicly Available Full Text
This content will become publicly available on November 10, 2018
Publisher's Accepted Manuscript

Save / Share:
  • The goal of successful Radiotherapy requires that treatment machines deliver a prescribed dose distribution to a prescribed target volume. The use of specially designed treatment aids and accessories can assist the radiotherapist in achieving this goal. This paper describes some of the recent developments in this area and suggests possible areas for future development efforts.
  • Second malignancies are one of the known complications of cancer treatment. Several recent studies which have quantified the risk of treatment-induced cancers following gynecologic malignancies are reviewed. After cervical cancer, there is a 9% excess risk of second cancers, of which only 5% could be attributed to radiation therapy. Most of the treatment-related malignancies after cervical or endometrial cancer are solid tumors occurring within the radiation field. Following both cervical and endometrial cancer, there is a small increased risk of leukemia associated with radiation therapy. In contrast, after ovarian cancer, there is significantly increased risk of leukemia related to treatmentmore » with alkylating agents, which varies by drug type and total dose. The cumulative risk of leukemia and preleukemia following single agent melphalan is 11.2% +/- 2.6% at ten years; the risk after cyclophosphamide is 5.4% +/- 3.2%. Overall, the risk of second malignancies following treatment of gynecologic cancers is small. 38 references.« less
  • Objectives: The majority of childhood cancer patients now achieve long-term survival, but the treatments that cured their malignancy often put them at risk of adverse health outcomes years later. New cancers are among the most serious of these late effects. The aims of this review are to compare and contrast radiation dose–response relationships for new solid cancers in a large cohort of childhood cancer survivors and to discuss interactions among treatment and host factors. Methods: This review is based on previously published site-specific analyses for subsequent primary cancers of the brain, breast, thyroid gland, bone and soft tissue, salivary glands,more » and skin among 12,268 5-year childhood cancer survivors in the Childhood Cancer Survivor Study. Analyses included tumor site–specific, individual radiation dose reconstruction based on radiation therapy records. Radiation-related second cancer risks were estimated using conditional logistic or Poisson regression models for excess relative risk (ERR). Results: Linear dose–response relationships over a wide range of radiation dose (0-50 Gy) were seen for all cancer sites except the thyroid gland. The steepest slopes occurred for sarcoma, meningioma, and nonmelanoma skin cancer (ERR/Gy > 1.00), with glioma and cancers of the breast and salivary glands forming a second group (ERR/Gy = 0.27-0.36). The relative risk for thyroid cancer increased up to 15-20 Gy and then decreased with increasing dose. The risk of thyroid cancer also was positively associated with chemotherapy, but the chemotherapy effect was not seen among those who also received very high doses of radiation to the thyroid. The excess risk of radiation-related breast cancer was sharply reduced among women who received 5 Gy or more to the ovaries. Conclusions: The results suggest that the effect of high-dose irradiation is consistent with a linear dose–response for most organs, but they also reveal important organ-specific and host-specific differences in susceptibility and interactions between different aspects of treatment.« less
  • Zidovudine was present in the semen and serum of six patients with acquired immunodeficiency syndrome or the related complex who were receiving 200 mg of the drug orally every four to six hours. Mean semen zidovudine levels (as measured by a new radioimmunoassay) in samples collected 0.75 to 1.25 hours after oral dosing were 3.63 to 7.19 ..mu..mol/L. Levels in semen samples collected 3.0 to 4.5 hours after oral dosing were 1.68 to 6.43 ..mu..mol/L. These values are above the in vitro minimum inhibitory concentration for the human immunodeficiency virus type 1 (HIV-1). Mean serum concentrations at the early andmore » late times after oral dosing were 0.22 to 3.07 ..mu..mol/L and 0.10 to 1.42 ..mu..mol/L, respectively. Ratios of semen/serum zidovudine levels ranged from 1.3 to 20.4. It is possible that a pH-dependent trapping mechanism, which has been described in the prostate for other antibiotics, was responsible for the relatively high semen levels observed.« less
  • The risk of a second primary cancer arising in the head and neck, following surgical or radiation treatment of an initial primary cancer in the head and neck, was evaluated for 2,151 patients whose first cancers were diagnosed and treated at UCLA between 1955 and 1979. Based on follow-up data ranging from 5 to 30 years, the rate of development of second cancers of the head and neck was in excess of 2.5 per 1000 person-years at risk. There was no statistically significant difference in the frequency or post-treatment interval of second primary cancers related to the type of treatmentmore » of the first cancer, whether that was surgery, radiation therapy, or surgery plus radiation therapy.« less